Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1993 1
1997 2
1999 2
2000 1
2002 1
2003 2
2004 3
2005 2
2007 4
2008 2
2009 8
2010 4
2011 8
2012 7
2013 9
2014 3
2015 11
2016 9
2017 9
2018 5
2019 8
2020 6
2021 14
2022 11
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, Nawale K, Jogdhankar S, Tambe R, Dhumal S, Sawant R, Alone M, Karla D, Peelay Z, Pathak S, Balaji A, Kumar S, Purandare N, Agarwal A, Puranik A, Mahajan A, Janu A, Kumar Singh G, Mittal N, Yadav S, Banavali S, Prabhash K. Patil VM, et al. J Clin Oncol. 2023 Jan 10;41(2):222-232. doi: 10.1200/JCO.22.01015. Epub 2022 Oct 20. J Clin Oncol. 2023. PMID: 36265101 Clinical Trial.
PURPOSE: The regimens approved for the treatment of advanced head and neck squamous cell carcinoma are accessible to only 1%-3% of patients in low- and middle-income countries because of their cost. ...METHODS: This was a randomize …
PURPOSE: The regimens approved for the treatment of advanced head and neck squamous cell carcin …
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
Xu Y, Gao Z, Hu R, Wang Y, Wang Y, Su Z, Zhang X, Yang J, Mei M, Ren Y, Li M, Zhou X. Xu Y, et al. J Immunother Cancer. 2021 Oct;9(10):e002699. doi: 10.1136/jitc-2021-002699. J Immunother Cancer. 2021. PMID: 34697216 Free PMC article.
BACKGROUND: Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNSCC) owing to the limited efficacy of anti-epidermal growth factor receptor (EGFR) therapy. ...
BACKGROUND: Combination therapy has been explored for advanced head and neck squamous cell carc …
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
BACKGROUND: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. ...
BACKGROUND: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous …
Six-MicroRNA Prognostic Signature in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.
Worakitchanon W, Panvongsa W, Siripoon T, Kitdumrongthum S, Wongpan A, Arsa L, Trachu N, Jinawath N, Chairoungdua A, Ngamphaiboon N. Worakitchanon W, et al. JCO Precis Oncol. 2023 May;7:e2300003. doi: 10.1200/PO.23.00003. JCO Precis Oncol. 2023. PMID: 37163716
Therefore, we aimed to identify a prognostic miRNA signature from The Cancer Genome Atlas (TCGA) database and validate it in the Ramathibodi (RA) locally advanced head and neck squamous cell carcinoma (LA-HNSCC) cohort. METHODS: Th …
Therefore, we aimed to identify a prognostic miRNA signature from The Cancer Genome Atlas (TCGA) database and validate it in the Ramathibodi …
Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.
Sanz-Garcia E, Zou J, Avery L, Spreafico A, Waldron J, Goldstein D, Hansen A, Cho BCJ, de Almeida J, Hope A, Hosni A, Hahn E, Perez-Ordonez B, Zhao Z, Smith C, Zheng Y, Singaravelan N, Bratman SV, Siu LL. Sanz-Garcia E, et al. Cell Death Differ. 2024 Apr;31(4):460-468. doi: 10.1038/s41418-024-01272-y. Epub 2024 Feb 26. Cell Death Differ. 2024. PMID: 38409276 Free PMC article.
Up to 30% of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) relapse. ...
Up to 30% of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC …
Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma.
Li X, Fang Q, Du W, Zhang X, Dai L, Qiao Y. Li X, et al. BMC Cancer. 2021 May 27;21(1):622. doi: 10.1186/s12885-021-08373-8. BMC Cancer. 2021. PMID: 34044810 Free PMC article. Clinical Trial.
BACKGROUND: This study aimed to explore the efficacy and safety of sintilimab combined with induction chemotherapy (IC) in locally advanced head and neck squamous cell carcinoma (HNSCC) patients. METHODS: A total of 163 patients we …
BACKGROUND: This study aimed to explore the efficacy and safety of sintilimab combined with induction chemotherapy (IC) in locally advanc …
AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.
Fulcher CD, Haigentz M Jr, Ow TJ; Education Committee of the American Head and Neck Society (AHNS). Fulcher CD, et al. Head Neck. 2018 Apr;40(4):676-686. doi: 10.1002/hed.25025. Epub 2017 Nov 24. Head Neck. 2018. PMID: 29171929 Free PMC article. Review.
This article is a continuation of the "Do You Know Your Guidelines" series, initiated by the Education committee of the American Head and Neck Society. Treatment guidelines for advanced head and neck squamous cell carcinoma are rev …
This article is a continuation of the "Do You Know Your Guidelines" series, initiated by the Education committee of the American Head and Ne …
Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma.
Erul E, Guven DC, Ozbay Y, Altunbulak AY, Kahvecioglu A, Ercan F, Yesil MF, Ucdal MT, Cengiz M, Yazici G, Kuscu O, Suslu N, Gullu I, Onur MR, Aksoy S. Erul E, et al. Biomark Med. 2023 Jan;17(2):87-99. doi: 10.2217/bmm-2022-0748. Epub 2023 Apr 12. Biomark Med. 2023. PMID: 37042459
Materials & methods: Disease-free survival and overall survival were compared according to cervical computed tomography for radiotherapy in 123 sarcopenic and non-sarcopenic patients with locally advanced head and neck squamous cell …
Materials & methods: Disease-free survival and overall survival were compared according to cervical computed tomography for radiotherapy …
128 results